Atlas Trials

Pediatric Solid Tumor

23 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Pediatric Solid Tumor

RecordFirmDate
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) (NCT04897321)St. Jude Children's Research Hospital2022-07-06
Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy (NCT05322187)RenJi Hospital2022-04-10
UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors (NCT06760117)Sun Yat-sen University2022-01-01
Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents (NCT05151718)Institut Claudius Regaud2021-09-30
A Prediction Model of Hematological Recovery After High-dose Chemotherapy in Pediatric Solid Tumor (NCT05024331)Samsung Medical Center2021-07-30
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors (NCT04222413)National Cancer Institute (NCI)2020-10-27
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (NCT04483778)Seattle Children's Hospital2020-07-13
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (NCT03618381)Seattle Children's Hospital2019-06-18
Effects of Music and Maternal Voice on Sedation Depth and Sedative Use During Pediatric Magnetic Resonance Imaging. (NCT04944875)TC Erciyes University2019-05-01
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas (NCT03478462)Cellectar Biosciences, Inc.2019-04-30
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors (NCT03739827)National Cancer Institute (NCI)2019-01-28
A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) (NCT03455140)University of Birmingham2018-08-28
Pegteograstim in Children With Solid Tumors (NCT02787876)Samsung Medical Center2016-10-04
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors (NCT02564198)Eli Lilly and Company2015-12-11
The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study (NCT02520713)Dana-Farber Cancer Institute2015-10-01
iCAT for Recurrent/Refractory/HR Solid Tumors (NCT01853345)Dana-Farber Cancer Institute2012-08-01

Track Pediatric Solid Tumor automatically

Every clearance here is in the API, with alerts when new ones post.